Natural Capsules Ltd

Natural Capsules Limited submitted a certificate to the BSE Limited and National Stock Exchange of India Limited on October 9, 2026, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, with Cameo Corporate Services Limited acting as the Registrar & Share Transfer Agent.

Natural Capsules Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for equity shares will be closed for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of financial results for the quarter ended September 30, 2026, with the board meeting date to be announced later.

Natural Capsules Limited convened its 1st Extraordinary General Meeting on Wednesday, September 9, 2026, via video conference, where shareholders approved a special resolution for the issuance of equity shares and warrants convertible into equity shares on a preferential basis. Mr. Tekkar Yashwanth Prabhu, Chairman, presided over the meeting, which was attended by 31 members constituting the requisite quorum, and Mr. Sunil L Mundra, Managing Director, addressed the meeting regarding the preferential issue. The results of the voting will be declared upon receipt of the Scrutinizer's report and submitted to the stock exchanges separately.

Natural Capsules Limited announced the results of its 1st Extraordinary General Meeting held on Wednesday, September 9, 2026, disclosing that two special resolutions were passed with the requisite majority. The resolutions pertained to the issuance of equity shares and warrants convertible into equity shares on a preferential basis. The company, along with Deepak Sadhu, Practicing Company Secretary, conducted the e-voting process, which commenced on September 4, 2026, and concluded on September 8, 2026, with a final 15-minute window after the meeting.

Natural Capsules is undertaking a preferential allotment of 4,50,000 convertible warrants to Mr. Sunil Mundra, a promoter, to raise Rs 8.01 Crores, approximately $9.7 million USD. The funds will primarily be used to meet working capital requirements, with a potential reallocation to capital expansion initiatives if opportunities arise. Following the allotment and assuming full conversion of warrants, the promoter and promoter group’s shareholding will increase to 53.44%, while public shareholding will decrease to 46.56%. The allotment complies with Securities and Exchange Board of India (ICDR) Regulations, and the company has obtained a certificate confirming this compliance. The funds are expected to be utilized within 18 months from the allotment date, September 10, 2026.

Natural Capsules Limited will hold a board meeting on Wednesday, September 2, 2026, at shorter notice to consider and evaluate an updated valuation report from a registered valuer concerning a proposed preferential issue of equity shares or convertible securities, as well as to approve a revised issue/allotment price and quantity of equity shares and warrants, and a revised notice and schedule for the general meeting. The meeting is being convened due to the urgent need to respond to queries from the BSE and NSE regarding the valuation report and to adhere to statutory timelines, with the trading window for designated persons remaining closed until 48 hours after the board meeting's outcome.

Natural Capsules Limited has informed the BSE Limited and National Stock Exchange of India Limited that September 2nd, 2026, has been set as the record date for an Extraordinary General Meeting (EGM) scheduled for September 9th, 2026.

Shareholders of an unnamed company are being asked to approve a preferential allotment of equity shares and warrants to Mr. Sunil Laxminarayan Mundra, a promoter, and potentially others, to raise capital. The allotment, requiring a special resolution, will increase Mr. Mundra’s shareholding and dilute public ownership, with the share price determined according to Securities and Exchange Board of India (SEBI) regulations, using a pricing certificate from M/s. P. Chandrasekar, LLP Chartered Accountant, available on the company's website. While the company states there will be no change in management or control and that the promoters are not classified as willful defaulters or fugitive economic offenders, shareholders may seek clarification on the specific use of the raised funds and the pricing methodology. The transaction is being pursued under the Companies Act, 2013, and SEBI (ICDR) Regulations, and is subject to lock-in periods as mandated by those regulations.

Natural Capsules Ltd share price slipped 1.37% to Rs 166.15 after the company's net profit rose by 15.26% to Rs 5.74 crore, while revenue from operations declined 16.66% to Rs 48.71 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, rising 4.31%. It has marginally improved by 0.98% over last one week and advanced by 11.49% in last one month while the market capitalization of Natural Capsules Ltd has inched up 8.62% and 4.55% in the same period respectively. Profit before tax (PBT) of Natural Capsules Ltd stood at Rs 5.83 crore in Q2 FY26, declining 3.80% year-on-year, and advancing by 14.76% quarter-on-quarter. EBITDA came in at Rs 1 crore, rallying 2975.00% YoY and tanking 315.79% sequentially. Total expenses contracted by 15.44% to Rs 51.92 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 28.92 crore, slightly declining by 1.87% YoY, while employee benefits expense was at Rs 5.24 crore, softening 4.38% YoY. For the TTM ended FY26, revenue from operations rose 10.63% to Rs 187.2 crore, while net profit tumbled by 4077.42% to Rs 24.66 crore, compared to previous TTM. EBITDA soared by 2384% to Rs 3.29 crore, and PBT collapsed by 1100.72% to Rs 27.92 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 10.92 crore in FY26, as against Rs 26.75 crore in FY25. Natural Capsules Ltd crashed 22.05% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.04% during the same period.

Natural Capsules Limited will consider a proposal to raise funds through the issuance of equity shares, convertibles, or other eligible securities on a preferential basis at a board meeting scheduled for Wednesday, August 12, 2026, according to a regulatory filing with the BSE Limited and National Stock Exchange of India Limited. The company also noted that the trading window for equity shares remains closed for designated persons and their immediate relatives until after the declaration of financial results for the quarter ended June 30, 2026.